

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
10 January 2002 (10.01.2002)

PCT

(10) International Publication Number
WO 02/03065 A1

- (51) International Patent Classification⁷: **G01N 33/53**, 33/569
- (74) Agent: **BALDWIN SHELSTON WATERS**; 60 Margaret Street, Sydney, NSW 2000 (AU).
- (21) International Application Number: **PCT/AU01/00795**
- (22) International Filing Date: **3 July 2001 (03.07.2001)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
PQ 8541 **3 July 2000 (03.07.2000)** **AU**
- (71) Applicant (for all designated States except US): **HELLRAD PTY LTD** [AU/AU]; Charters Pty Ltd, 8th Floor, 19 Pier Street, Perth, WA 6000 (AU).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **CLANCY, Robert**, Llewellyn [AU/AU]; 11 High Street, Newcastle, NSW 2300 (AU). **BORODY, Thomas, Julius** [AU/AU]; 144 Great North Road, Five Dock, NSW 2046 (AU). **PANG, Gerald** [AU/AU]; 4/25 Billyard Avenue, Elizabeth Bay, NSW 2011 (AU). **REN, Zhigang** [CN/AU]; 12B Vitre Street, Lambton, NSW 2299 (AU).
- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/03065 A1

(54) Title: **METHODS FOR MONITORING TREATMENT OF HELICOBACTER INFECTION AND FOR PREDICTING THE LIKELIHOOD OF SUCCESSFUL ERADICATION**

(57) Abstract: The present invention relates to methods for monitoring treatment of *Helicobacter* infection and in particular to methods for monitoring eradication of *Helicobacter pylori* infection using immunoglobulin G2 (IgG2). The invention also relates to methods for predicting the likelihood of successful eradication of *Helicobacter* infection in a subject to be treated or being treated for the infection and in particular, to methods for predicting the likelihood of successful eradication including determining the levels of interleukin-4, interferon- γ and IgG in the subject to be, or being treated.

BEST AVAILABLE COPY

METHODS FOR MONITORING TREATMENT OF HELICOBACTER INFECTION AND FOR PREDICTING THE LIKELIHOOD OF SUCCESSFUL ERADICATION

TECHNICAL FIELD

The present invention relates to methods for monitoring treatment of *Helicobacter* infection and in particular to methods for monitoring eradication of *Helicobacter pylori* infection using immunoglobulin G2 (IgG2). The invention also relates to methods for predicting the likelihood of successful eradication of *Helicobacter* infection in a subject to be treated or being treated for the infection and in particular, to methods for predicting the likelihood of successful eradication including determining the levels of interleukin-4, interferon- γ and IgG in the subject to be, or being treated.

BACKGROUND ART

Any discussion of the prior art throughout the specification should in no way be considered as an admission that such prior art is widely known or forms part of common general knowledge in the field.

Helicobacter pylori infection is now recognised as an essential pre-requisite for the development of gastric cancer. About 30% of the population become infected with this bacterium and commonly present with chronic gastritis. This may be complicated by gastric or duodenal ulceration, or may present as non-ulcer dyspepsia. A sizeable number of carriers are asymptomatic. However, in a small number of patients with *H. pylori*, their condition evolves through stages (including epithelial cell metaplasia and dysplasia) into neoplasia.

Current Management Practice of *H. pylori* Infection

Eradication of infection with antibiotics induces an 80-90% cure rate of peptic ulceration. A widely accepted treatment paradigm is based on detection of infection using antibody assays, followed by combination antibiotic therapy without prior endoscopic diagnosis. Endoscopy, before eradication therapy is generally accepted when 'danger' symptoms (eg, severe pain, bleeding) occur, or a significant risk of gastric cancer is present. However, endoscopy is a procedure which is associated with its own risks and is to be avoided if possible.

H. pylori initiates an IgG antibody response in saliva as well as serum. The serum IgG antibody is the basis of non-invasive diagnosis. Eradication of infection is followed by a very slow fall in serum antibody levels. There has been a study which suggests that IgG antibody levels at 6 months may be of value in assessing successful eradication. Saliva levels of IgG antibody however fall much quicker following eradication, with levels at 6 weeks regularly less than 80% of those prior to antibiotic therapy.

The concept that saliva IgG antibody levels may predict successful eradication, while attractive, proved not to be a practical proposition for monitoring of progress of treatment or eradication of *Helicobacter* because total IgG antibody levels were unstable to the extent that a viable test in clinical circumstances proved unreliable. At present, no non-invasive stable test exists which would allow successful monitoring of treatment designed to eradicate *Helicobacter* infection.

Further, in addition to monitoring eradication of *H. pylori* in individuals treated, it would be desirable to have a test which could be used prior to, or during treatment to determine the likelihood of successful eradication of *H. pylori*.

It is an object of the present invention to overcome or ameliorate at least one of the disadvantages of the prior art, or to provide a useful alternative.

SUMMARY OF THE INVENTION

According to a first aspect there is provided a method of monitoring eradication of *Helicobacter* infection in a subject treated for the infection, including:

- a) determination of IgG2 anti-*H. pylori* antibody level in a saliva sample;
- b) comparison of the IgG2 anti-*H. pylori* antibody level with a predetermined control IgG2 anti-*H. pylori* antibody level, wherein a reduction in the level of IgG2 anti-*H. pylori* antibody in the saliva sample compared to the control indicates eradication of *Helicobacter*.

According to a second aspect there is provided a method of monitoring efficacy of treatment of *Helicobacter* infection in a subject treated for the infection, including:

- a) determination of IgG2 anti-*H. pylori* antibody level in a saliva sample;
- b) comparison of the IgG2 anti-*H. pylori* antibody level with a predetermined control IgG2 anti-*H. pylori* antibody level, wherein a reduction in the level of IgG2 anti-*H. pylori* antibody in the saliva sample compared to the control indicates efficacious treatment of *Helicobacter*.

According to a third aspect there is provided a method of monitoring relapse or reinfection with *Helicobacter* in a subject treated for infection with *Helicobacter*, including:

- a) determination of IgG2 anti-*H. pylori* antibody level in a saliva sample;
- b) comparison of the IgG2 anti-*H. pylori* antibody level with a predetermined control IgG2 anti-*H. pylori* antibody level, wherein an increase in the level of IgG2 anti-*H. pylori* antibody in the saliva sample compared to the control indicates relapse or reinfection with *Helicobacter*.

According to a fourth aspect there is provided a method of detecting unresponsiveness of a subject to treatment of *Helicobacter* infection, including:

- a) determination of IgG2 anti-*H. pylori* antibody level in a saliva sample;

b) comparison of the IgG2 anti-*H. pylori* antibody level with a predetermined control IgG2 anti-*H. pylori* antibody level, wherein lack of change in the level of IgG2 anti-*H. pylori* antibody in the saliva sample compared to the control indicates lack of response to treatment.

According to a sixth aspect there is provided a kit for monitoring treatment of *Helicobacter* infection, including,

- a) *Helicobacter* antigen
- b) reagent for determining IgG2 subclass antibody.

Preferably, the IgG2 anti-*H. pylori* antibody is detected by a near-subject assay. The assay may, however, also be a laboratory-based test. Preferably, the assay is an antibody assay although it will be understood that other known methods of measurement can also be effectively used. Most preferably, the assay is an immunoassay such as ELISA, RIA or a similar assay format.

Control levels of IgG2 anti-*H. pylori* antibody can be established in samples of saliva obtained from normal individuals, ie. those not having an established *H. pylori* infection. It is preferred however that control levels of IgG2 be determined in subject's own saliva prior to commencement of treatment for infection or, if monitoring relapse or reinfection, the levels of salivary IgG2 following successful eradication of *Helicobacter*.

According to a seventh aspect, the present invention provides a method of predicting the likelihood of successful eradication of *Helicobacter* infection in a subject to be treated or being treated for the infection, including:

- (i) determination of IL-4 level in a sample from the subject;
- (ii) comparison of the IL-4 level with a predetermined control or standard IL-4 level,
- (iii) wherein a level of IL-4 in the sample from the subject above the control or standard IL-4 level is predictive of the likelihood of successful eradication and a level of IL-4 below the control or standard IL-4 level is predictive of the likelihood of eradication failure.

Preferably, the sample is a blood sample.

Preferably, the IL-4 is detected by an immunoassay and more preferably, it is determined by ELISA.

The skilled addressee will readily be able to identify a suitable control or standard IL-4 level. For example, the control or standard level of IL-4 may be established from analysis of samples obtained from subjects not infected by *H. pylori* and/or subjects having successfully eradicated *H. pylori* and/or subjects infected by *H. pylori*.

According to an eighth aspect, the present invention provides a method of predicting the likelihood of successful eradication of Helicobacter infection in a subject to be treated or being treated for the infection, including:

- (i) determination of interferon- γ (INF- γ) level in a sample from the subject;
- (ii) comparison of the INF- γ level with a predetermined control or standard INF- γ level,
- (iii) wherein a level of INF- γ in the sample from the subject below the control or standard INF- γ level is predictive of the likelihood of successful eradication and a level of INF- γ above the control or standard level is predictive of the likelihood of eradication failure.

Preferably, the INF- γ level is determined in a blood sample.

Preferably, the INF- γ level is detected by an immunoassay and preferably the assay is ELISA.

The skilled addressee will readily be able to establish a suitable control or standard. For example, the control or standard level of INF- γ may be established from analysis of samples obtained from subjects not infected by *H. pylori* and/or subjects having successfully eradicated *H. pylori* and/or subjects infected by *H. pylori*.

According to a ninth aspect, the present invention provides a method of predicting the likelihood of successful eradication of Helicobacter infection in a subject to be treated or being treated for the infection, including:

- (i) determination of immunoglobulin G (IgG) level in a sample from the subject;
- (ii) comparison of the IgG level with a predetermined control or standard IgG level,
- (iii) wherein a level of IgG in the sample from the subject below the control or standard level is predictive of the likelihood of successful eradication and a level of IgG above the control or standard level is predictive of the likelihood of eradication failure.

Preferably, the IgG level is determined in a serum sample and, more preferably, the sample is a saliva sample.

The skilled addressee will readily be able to establish a suitable control or standard level of IgG. For example, the control or standard level of IgG may be established from analysis of samples obtained from subjects not infected by *H. pylori* and/or subjects having successfully eradicated *H. pylori* and/or subjects infected by *H. pylori*.

According to a tenth aspect, the present invention provides a method of predicting the likelihood of successful eradication of Helicobacter infection in a subject to be treated or being treated for the infection, including:

- (i) determination a combination of IL-4 and/or INF- γ and/or IgG levels in a sample from the subject;
- (ii) comparison of the IL-4 and/or INF- γ and/or IgG levels with a predetermined control or standard IL-4 and/or INF- γ and/or IgG level respectively,

wherein a level of IL-4 in the sample from the subject above the control or standard level is predictive of the likelihood of successful eradication and a level of IL-4 below the control or standard level is predictive of the likelihood of eradication failure, and

wherein a level of INF- γ in the sample from the subject below the control or standard level is predictive of the likelihood of successful eradication and a level of IFN- γ above the control or standard level is predictive of the likelihood of eradication failure, and

wherein a level of IgG in the sample from the subject below the control or standard level is

predictive of the likelihood of successful eradication and a level of IgG above the control or standard level is predictive of the likelihood of eradication failure.

BRIEF DESCRIPTION OF THE FIGURES

Figure 1 Stability of salivary IgG2 anti-*Helicobacter pylori* antibody.

Figure 2 Salivary IgG (panel A) and IgG2 (panel B) anti-*H. pylori* antibody before and after eradication of *H. pylori*.

Figure 3 Salivary IgG (panel A) and IgG2 (panel B) anti- *H. pylori* antibody in subject with and without *H. pylori* infection.

Figure 4 Correlation between IL-4 production in whole blood and gastric tissue cultures.

Whole blood cultures or gastric antrum biopsy cultures were incubated for 24 hours at 37°C, after which time the levels of IL-4 were measured by ELISA capture assay. The results shown a correlation between mucosal and whole blood IL-4 ($p < 0.001$).

Figure 5 Levels of IL-4 in whole blood culture stimulated with *H. pylori* AGE antigen.

Peripheral blood obtained from subjects with or without *H. pylori* infection, or with eradication failure was added to equal volume of AIM-V culture medium containing graded concentrations of *H. pylori* AGE antigen as indicated. After 24 hours of culture, levels of IL-4 were measured by ELISA capture assay. Results shown are the mean \pm standard error of the mean. *: $p < 0.05$: compared with *H. pylori*-eradicated subjects; ¶: $p < 0.01$ and $p < 0.05$ compared with the values from subjects with *H. pylori*-eradicated and *H. pylori*-positive, respectively.

Figure 6 IFN- γ production in response to *H. pylori* acid-glycine extract stimulation in whole blood. Peripheral blood was collected from individual subject and cultured in the presence of graded concentration of *H. pylori* AGE antigen for 24 hours. Culture supernatants were collected and assayed for IFN- γ by ELISA. Results shown were mean \pm standard error of the mean. NS: Not Significant.

Figure 7 Levels of specific *H. pylori* IgG antibody in serum and saliva. Serum and saliva samples were collected from individual subjects. Levels of specific *H. pylori* IgG were measured by ELISA. Results shown were mean \pm standard error of the mean. *: $p < 0.05$ compared with mean from *H. pylori*-positive group; NS: Not Significant.

DESCRIPTION OF THE PREFERRED EMBODIMENTS

It has surprisingly been found that salivary IgG2 anti-*H. pylori* antibody is stable and allows a reliable test to be developed for monitoring progress of treatment and/or eradication of *Helicobacter pylori* infection in a subject undergoing treatment.

It was previously known that IgG anti-*H. pylori* antibody levels in blood and gastric mucosa can be used as an indicator of *H. pylori* status. There has been an attempt to use IgG anti-*H. pylori* antibody in saliva for a similar purpose but it proved to be unstable in such a sample. From the following examples it will be understood that while IgG anti-*H. pylori* may be useful as a general indicator of *H. pylori* status, it is the measurement of the IgG2 subclass anti-*H. pylori* antibody which allows a stable treatment monitoring test to be developed.

It has further surprisingly been found that IL-4 levels can be used as a predictor of successful eradication of *H. pylori*. It is envisaged that an IL-4 test could be used prior to, or during the treatment of *H. pylori* infection in order to predict the likelihood of eradication.

Techniques for measurement of antibodies and IL-4 in human samples are well-known in the art and protocols and reagents are readily available. Examples of some of the techniques used are indicated below as an illustration of how some measurements may be performed.

Unless indicated otherwise, standard techniques which can be ascertained from standard texts and laboratory manuals may be employed.

The invention will now be described in more detail with reference to non-limiting examples.

EXAMPLES

Example 1 Determination of antibody levels in saliva samples

Sample Collection

Saliva samples were collected from 4 patients infected with *H. pylori* who were treated with eradication triple therapy comprised of amoxycillin, omeprazole and clarithromycin for seven days. Samples were taken before treatment and after 10 days of eradication therapy.

H. pylori antigen preparation

H. pylori NCTC 11637 strain was used for *H. pylori* antigen preparation according to modified methods described by Goodwin (#208). Protein concentration in the extract was measured using a bio-rad kit (Bio-rad laboratories Australia). Aliquots were stored at -70°C.

Antibody detection by ELISA

For saliva anti-*H. pylori* antibody detection, wells of a 96-well flat-bottomed microtiter Polysorb plate (Nunc, Denmark) were coated with 7 µg/mL of *H. pylori* antigen at 4°C overnight. After washing and blocking the plates with 5% skim milk (Diploma, Australia) in PBS-Tween 20, saliva samples at 1:2 dilution with 2% PEG 6000 were added to individual wells in triplicate. After incubation, the wells were washed and horseradish peroxidase conjugated-sheep anti-IgG or anti-IgG2 (Silenus, Australia) at 1:2000 dilution was added to each well. Following a further incubation, the plates were washed and then tetramethyl benzidine (TMB) substrate (Sigma, USA) was added to each well. The reaction was stopped using 1 mol/L H₂SO₄ and the absorbance was read at 450 nm in an ELISA plate reader (Bio-Rad 450, Japan). The results were expressed as ELISA INDEX being the mean OD₄₅₀ of a given saliva sample divided by the mean OD₄₅₀ of the calibrating sample. Positive and

negative quality control samples were included in each run to control for intra- and inter-assay variation.

Saliva samples were obtained from 5 subjects infected with *H. pylori*. The samples were tested for IgG2 and total IgG anti-*H. pylori* antibody by the ELISA assay either fresh or after storage for up to 12 months. The results show that IgG2 antibody levels were more stable than IgG antibody levels (Figure 1). Hence, IgG2 antibody is a reliable and a sensitive indicator of infection status due to its stability during storage and assay.

Example 2 Anti-*H. pylori* antibody levels in saliva from patients undergoing eradication therapy.

Saliva samples from subjects undergoing antibiotic eradication therapy were tested for anti-*H. pylori* antibody using the immunoassay method described in Example 1.

IgG and IgG2 antibody was measured before and after treatment with antibiotics. Ten days after treatment IgG2 antibody levels fell quicker than total IgG antibody levels (Figure 2A and 2B).

In a separate study it was shown that saliva from subjects with *H. pylori* infection have markedly elevated levels of IgG2 (Figure 3A) when compared to subjects without infection (Figure 3B). Subjects who failed to ultimately eradicate the infection did not demonstrate a significant drop in the level of IgG2 anti-*H. pylori* antibody.

Example 3 - Interleukin-4/IFN- γ and IgG Studies

Subjects

Fifty-two subjects referred for investigation of dyspepsia, and 11 subjects with persistent *H. pylori* infection following one or more courses of antibiotics, were recruited for this study. Subjects with dyspepsia had not taken antibiotics within three months of the study. The study was approved by the Ethics Committee of the Centre for Digestive Diseases, Sydney,

Australia. Informed consent was obtained from all patients. Multiple biopsy specimens were obtained during upper gastrointestinal endoscopy from the antrum and the body of the stomach to be used for tissue culture, histology and a urease test (CLO test, Delta West, WA, Australia). Blood samples were incubated at 37°C within 2 hours of collection. Serum was stored at -70°C for *H. pylori* specific antibody.

Saliva sample collection

Saliva samples were collected before the endoscopy procedure. Samples were centrifuged at 1000 x g for 10 minutes at 4°C, and aliquots were stored at -70°C.

Biopsy culture

Gastric biopsy tissues were weighted and cultured at a ratio of 50 µL serum-free AIM-V medium (Life Technology, Australia) per mg tissue (wet weight) for 24 hours. The culture supernatants were collected and centrifuged. Aliquots were stored at -70°C until assay.

H. pylori antigen preparation

H. pylori antigens from the NCTC 11637 strain were prepared by acid-glycine extraction (AGE) according to the method described by Goldwin et al (*J Infect Dis* 1987; 155:488-94).

H. pylori AGE was used for cell culture and specific antibody measurement.

ELISA capture assay for IL-4 in whole blood culture

Cytokine levels in whole blood culture were measured following the method described previously (Ren et al, *Helicobacter* 2000; 5:135-41). Briefly, 150 µL of heparinized whole blood was added in triplicate to wells of a 96-well microtitre flat-bottomed plate pre-coated with mouse polyclonal anti-human IL-4 antibody (Endogen, MA, USA). An equal volume of AIM-V medium containing *H. pylori* AGE at either 0, 1 or 10 µg/mL was also loaded to wells. The cultures were incubated at 37°C with 5% CO₂ for 24 hours, after which time supernatants were collected for interferon-γ (IFN-γ) assay. The amount of 'captured' IL-4 was measured by ELISA as following. Briefly, after washing the plates, biotinylated mouse

monoclonal anti-human IL-4 antibody (Endogen, MA, USA) was added (0.5 µg/mL) to wells and incubated for 90 minutes at room temperature. The plates were then washed and incubated for a further 30 minutes at room temperature with streptavidin-conjugated horse-radish peroxidase (Selinus, Australia) at a 1:400 dilution. The plates were thoroughly washed with washing buffer and finally incubated for 10 minutes at room temperature with 3,3'-5,5' tetramethyl benzidine (TMB, Sigma-Aldrich, USA) substrate. The reaction was stopped using 1 mol/L H₂SO₄ and optical density at 450 nm (OD 450nm) was measured in an ELISA plate reader (Bio-Rad 450, Japan). Standard IL-4 (Endogen, MA, USA) was applied for each plate to control plate to plate variation. The limits of sensitivity for IL-4 was 9.4 pg/mL. The amount of IL-4 in samples was determined using a Softmax program (Version 2.3 FPU, USA).

IFN-γ ELISA assay

Wells of a 96-well flat-bottomed microtitre plate (Nunc, Denmark) were coated with mouse anti-human IFN-γ monoclonal antibody (Endogen, MA, USA) at 2 µg/mL overnight at 4°C. After washing and blocking, supernatants from whole blood culture or IFN-γ standards (Endogen, MA, USA) were added in duplicate, and incubated for 90 minutes. The plates were washed and biotinylated mouse monoclonal anti-human IFN-γ antibody (Endogen, MA, USA) was added (0.25 µg/mL). After 90 minutes incubation, the wells were washed and streptavidin-conjugated horse-radish peroxidase (Selinus, Australia) was applied at a 1:2000 dilution. The plates were washed and TMB chromagen (Sigma-Aldrich, USA) was added to each well. The absorbance was read at 450 nm in an ELISA plate reader (Bio-Rad 450, Japan). The limits of sensitivity for IFN-γ was 9.4 pg/mL. The amount of IFN-γ in samples was determined using a Softmax program (Version 2.3 FPU, USA).

Detection of *H. pylori* antibody

Wells of a 96-well flat-bottomed microtitre plate were coated with *H. pylori* AGE at 5

µg/mL at 4°C overnight. After washing and blocking, serum samples at 1:3000 dilution and saliva sample at 1:4 dilution were added to wells in triplicate. Horse-radish peroxidase conjugated-sheep anti-IgG (Selinus, Australia) was applied at 1:2000 dilution. Tetramethyl Benzidine (TMB) substrate (Sigma-Aldrich, USA) was used for colour development. The absorbance was read at 450 nm in an ELISA plate reader (Bio-Rad, 450, Japan). The results were expressed as ELISA Units against a reference standard of pooled positive sera. Intra- and inter-assay variation was less than 10%.

Statistical analysis

Data were expressed as mean \pm standard error (SE). Correlation Z test was used to test for a correlation between mucosal and blood cytokine production. Differences of means among patient groups were analysed by ANOVA. All statistical analysis were performed by using a StatView 4.5 software program (Abacus Concepts, California, USA). Significant difference was considered when p value was less than 0.05.

RESULTS

Subjects were divided into four groups according to *H. pylori* infection status and results of antibiotic treatment. There were 23 *H. pylori*-negative subjects; 20 *H. pylori*-positive subjects; 9 subjects with successful *H. pylori* eradication confirmed by histology or C¹⁴ breath test at 6-8 weeks after eradication therapy; and 11 subjects with *H. pylori* resistance following antibiotic therapy. Details of diagnosis and therapeutic regimens in subjects with eradication failure are shown in Table 1.

Comparison of blood and mucosal IL-4 response

To determine whether there is a correlation between blood and mucosal cytokine responses to *H. pylori* infection, levels of IL-4 production in whole blood cultures stimulated or unstimulated with *H. pylori* antigens, were compared with levels in gastric mucosa cultures (Fig. 1) (data from antigen stimulated cultures not shown). The results from *H. pylori* positive

(n=6) and negative subjects (n=11) and subjects with failed eradication (n=8) showed that IL-4 production in whole blood cultures (stimulated or unstimulated) correlated with that in gastric mucosa ($r^2=0.549$, $p<0.001$).

IL-4 and IFN- γ production in whole blood culture

Significantly lower levels of IL-4 were detected in whole blood stimulated or unstimulated with *H. pylori* AGE from subjects with eradication failure compared with subjects in whom *H. pylori* was successfully eradicated ($p<0.05$, 0 and 1.0 $\mu\text{g/mL}$ *H. pylori* AGE; $p<0.01$, 10 $\mu\text{g/mL}$ *H. pylori* AGE) or in subjects with untreated infection ($p<0.05$, 10 $\mu\text{g/mL}$ *H. pylori* AGE) (Fig 2). IL-4 levels were similar in non-infected and infected subjects, and were not significantly different when compared to subjects with successful eradication (though there was a trend towards increased levels following eradication). Although there was no statistically significant difference in the levels of IFN- γ between the different groups, lower levels were detected in subjects with successful *H. pylori* eradication (Fig. 3). Low levels of IL-4 secretion were seen in most subjects with ongoing infection with resistant *H. pylori*, irrespective of the number of courses of therapy (Table 2).

Anti-*H. pylori* IgG levels in serum and saliva

Both serum and saliva IgG antibody levels were significantly lower in non-infected subjects ($p<0.05$) and in subjects at 6-8 weeks after eradication therapy ($p<0.05$) than in subjects who were positive for *H. pylori*. For both saliva and serum antibody, a trend towards lower levels of antibody in those failing to eradicate infection was seen, but this was short of statistical significance (Fig. 4).

Table 1: Clinical Characterisation of Subjects with Failed Antibiotic Therapy

WO 02/03065

PCT/AU01/00795

No.	Age (years)	Diagnosis	Treatment Regimens Used	Number of Antibiotic Courses	Duration (months)
1	40	Hp-induced gastritis	metronidazole/amoxicillin/bismuth/ranitidine HCl	1	24
2	58	Hp-induced gastritis	clarithromycin/metronidazole/lansoprazole/amoxicillin	2	
3	55	Oesophagitis and Hp-induced gastritis	Losec HP7	1	12
			Klacid HP7	1	>3yrs
			Helidac/ranitidine HCl	1	15
			lansoprazole	1	
4	47	Hp-induced gastritis	Losec HP7	2	20
5	37	Hp-induced gastritis	metronidazole	1	5
			Losec HP7	3	
6	45	Hp-induced gastritis	Losec HP7/ranitidine HCl	3	28

PCT/AU01/00795

No.	Age (years)	Diagnosis	Treatment Regimens Used	Number of Antibiotic Courses	Duration (months)
7	27	Hp-induced gastritis	Losec HP7	3	6
8	33	Hp-induced gastritis and duodenal ulcer disease	clarithromycin/tetracycline/metronidazole/lansoprazole Helidac	1 2	>3yrs
9	26	Hp-induced gastritis	Losec HP7	2	10
10	47	Hp-induced gastritis	Losec HP7	3	>3yrs
11	73	Oesophagitis, Hp-induced gastritis and duodenal ulcer disease	Losec HP7	3	>3yrs

Hp= *Helicobacter pylori*; Helidac= bismuth/metronidazole/tetracycline; Klacid HP7= omeprazole/amoxicillin/clarithromycin;

Losec HP7= omeprazole/amoxicillin/clarithromycin

WO 02/03065

Table 2: IL-4 and *H. pylori* Antibody IgG in Subjects with Failure Eradication

Times of failure	No. Subjects	IL-4 levels (pg/mL)*			H. pylori Antibody IgG*	
		<i>H. pylori</i> antigen (0 µg/mL)	<i>H. pylori</i> antigen (1 µg/mL)	<i>H. pylori</i> antigen (10 µg/mL)	Serum (ELISA Unit)	Saliva (ELISA Unit)
One	1	20.76	28.21	44.20	214	116.3
Two	3	40.49 ± 29.36	54.07 ± 43.14	65.22 ± 45.86	224 ± 101.58	1000.2 ± 866.5
Three	5	45.16 ± 36.16	53.34 ± 44.34	55.63 ± 44.19	410.95 ± 167.29	418.9 ± 151.96
Four	2	18.82 ± 9.82	22.56 ± 13.58	12.60 ± 3.6	1453.6 ± 1244.4	523.7 ± 235.3

* Standard error of mean (SEM).

The skilled addressee will understand that, in light of the above, IL-4, INF- γ and IgG can be used to predict the likelihood of successful eradication of Helicobacter infection before or during treatment of the infection. As a corollary, it will be clear that the method can also be used to identify subjects unlikely to respond to treatment for

5 Helicobacter infection.

Although the invention has been described with reference to specific examples, it will be appreciated by those skilled in the art that the invention may be embodied in many other forms without departing from the spirit or intent of the inventive concept.

THE CLAIMS DEFINING THE INVENTION ARE AS FOLLOWS:

1. A method of monitoring eradication of *Helicobacter* infection in a subject treated for the infection, including:
 - 5 i) determination of IgG2 anti-*H. pylori* antibody level in a saliva sample;
 - ii) comparison of the IgG2 anti-*H. pylori* antibody level with a predetermined control IgG2 anti-*H. pylori* antibody level, wherein a reduction in the level of IgG2 anti-*H. pylori* antibody in the saliva sample compared to the control indicates eradication of *Helicobacter*.
- 10 2. A method of monitoring efficacy of treatment of *Helicobacter* infection in a subject treated for the infection, including:
 - i) determination of IgG2 anti-*H. pylori* antibody level in a saliva sample;
 - 15 ii) comparison of the IgG2 anti-*H. pylori* antibody level with a predetermined control IgG2 anti-*H. pylori* antibody level, wherein a reduction in the level of IgG2 anti-*H. pylori* antibody in the saliva sample compared to the control indicates efficacious treatment of *Helicobacter*.
- 20 3. A method of monitoring relapse or reinfection with *Helicobacter* in a subject treated for infection with *Helicobacter*, including:
 - i) determination of IgG2 anti-*H. pylori* antibody level in a saliva sample;

- ii) comparison of the IgG2 anti-*H. pylori* antibody level with a predetermined control IgG2 anti-*H. pylori* antibody level, wherein an increase in the level of IgG2 anti-*H. pylori* antibody in the saliva sample compared to the control indicates relapse or reinfection with
- 5 *Helicobacter*.
4. A method of detecting unresponsiveness of a subject to treatment of *Helicobacter* infection, including:
- (i) determination of IgG2 anti-*H. pylori* antibody level in a saliva sample;
- (ii) comparison of the IgG2 anti-*H. pylori* antibody level with a
- 10 predetermined control IgG2 anti-*H. pylori* antibody level, wherein lack of change in the level of IgG2 anti-*H. pylori* antibody in the saliva sample compared to the control indicates lack of response to treatment.
5. A method according to any one of claims 1 to 4, wherein the IgG2 anti-*H. pylori* antibody is detected by an immunoassay.
- 15 6. A method according to claim 5, wherein the assay is ELISA.
7. A method according to any one of claims 1 to 6, wherein the control levels of IgG2 anti-*H. pylori* antibody is established in samples of saliva obtained from subjects not infected by *H. pylori*.
8. A method according to any one of claims 1 to 6, wherein the control levels of IgG2
- 20 anti-*H. pylori* antibody are determined in subject's own saliva sample.
9. A kit for monitoring treatment of *Helicobacter* infection, including,
- (i) *Helicobacter* antigen
- (ii) reagent for determining IgG2 subclass antibody.

10. A method of predicting the likelihood of successful eradication of *Helicobacter* infection in a subject to be treated or being treated for the infection, including:
- (i) determination of IL-4 level in a sample from the subject;
 - (ii) comparison of the IL-4 level with a predetermined control or standard IL-4 level,
 - (iii) wherein a level of IL-4 in the sample from the subject above the control or standard IL-4 level is predictive of the likelihood of successful eradication and a level of IL-4 below the control or standard IL-4 level is predictive of the likelihood of eradication failure.
11. A method according to claim 10 wherein the sample is a blood sample.
12. A method according to claim 10 or claim 11, wherein the IL-4 is detected by an immunoassay.
13. A method according to claim 12, wherein the assay is ELISA.
14. A method according to any one of claims 10 to 13, wherein the control or standard level of IL-4 is established from analysis of samples obtained from subjects not infected by *H. pylori* and/or subjects having successfully eradicated *H. pylori* and/or subjects infected by *H. pylori*.
15. A method of predicting the likelihood of successful eradication of *Helicobacter* infection in a subject to be treated or being treated for the infection, including:
- (i) determination of interferon- γ (INF- γ) level in a sample from the subject;
 - (ii) comparison of the INF- γ level with a predetermined control or standard INF- γ level,

(iii) wherein a level of INF- γ in the sample from the subject below the control or standard INF- γ level is predictive of the likelihood of successful eradication and a level of INF- γ above the control or standard level is predictive of the likelihood of eradication failure.

- 5 16. A method according to claim 15 wherein the sample is a blood sample.
17. A method according to claim 15 or claim 16, wherein the INF- γ level is detected by an immunoassay.
18. A method according to claim 17, wherein the assay is ELISA.
19. A method according to any one of claims 15 to 18, wherein the control or standard
10 level of INF- γ is established from analysis of samples obtained from subjects not infected by *H. pylori* and/or subjects having successfully eradicated *H. pylori* and/or subjects infected by *H. pylori*.
20. A method of predicting the likelihood of successful eradication of Helicobacter infection in a subject to be treated or being treated for the infection, including:
- 15 (i) determination of immunoglobulin G (IgG) level in a sample from the subject;
- (ii) comparison of the IgG level with a predetermined control or standard IgG level,
- (iii) wherein a level of IgG in the sample from the subject below the control or
20 standard level is predictive of the likelihood of successful eradication and a level of IgG above the control or standard level is predictive of the likelihood of eradication failure.
21. A method according to claim 20 wherein the sample is a serum sample.

22. A method according to claim 20 wherein the sample is a saliva sample.
23. A method according to any one of claims 20 to 22, wherein the control or standard level of IgG is established from analysis of samples obtained from subjects not infected by *H. pylori* and/or subjects having successfully eradicated *H. pylori* and/or subjects infected by *H. pylori*.
24. A method of predicting the likelihood of successful eradication of Helicobacter infection in a subject to be treated or being treated for the infection, including:
- (i) determination a combination of IL-4 and/or INF- γ and/or IgG levels in a sample from the subject;
- (ii) comparison of the IL-4 and/or INF- γ and/or IgG levels with a predetermined control or standard IL-4 and/or INF- γ and/or IgG level respectively, wherein a level of IL-4 in the sample from the subject above the control or standard level is predictive of the likelihood of successful eradication and a level of IL-4 below the control or standard level is predictive of the likelihood of eradication failure, and wherein a level of INF- γ in the sample from the subject below the control or standard level is predictive of the likelihood of successful eradication and a level of IFN- γ above the control or standard level is predictive of the likelihood of eradication failure, and wherein a level of IgG in the sample from the subject below the control or standard level is predictive of the likelihood of successful eradication and a level of IgG above the control or standard level is predictive of the likelihood of eradication failure.

1/7




Figure 1

2/7




Figure 2




Figure 3




FIGURE 4




FIGURE 5

6/7




FIGURE 6

777




FIGURE 7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/AU01/00795

A. CLASSIFICATION OF SUBJECT MATTER		
Int. Cl. ⁷ : G01N 33/53, G01N 33/569		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED		
Minimum documentation searched (classification system followed by classification symbols)		
Int. Cl. ⁷ : G01N 33/53, G01N 33/569		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) STN, WPAT, JAPIO, esp@ce, PubMed, Delphion		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Australian patent 714222 by Cortecs Ltd open to public inspection in Australia 4 September 1996 (WO 96/25430 published 22 August 1996), which relates to a method of diagnosing H. pylori by detecting antibodies in saliva using antigens, see especially claims 8, 9 - 11, and related kit for use in diagnosis. See pages 1, 2, 4 - 6, and examples.	1-9
X	WO 98/32768 by Cortecs Ltd published 30 July 1998, which also relates to a method of diagnosing H. pylori by detecting antibodies in saliva using antigens, see especially claims 11 - 13, 15, 21 and related kit for use in diagnosis in the examples and claim 16. See pages 1, 2, 4, 5, 12, 17 and examples.	1-9
X	WO 00/29432 by Cortecs Ltd published 11 November 1999 also relates to a method of diagnosing H. pylori by detecting antibodies in saliva using antigens, see especially claims 11, 12, 14, 15, 19 and related kit for use in diagnosis in the examples and claim 20 - 22. See page 10 and examples.	1-9
<input type="checkbox"/> Further documents are listed in the continuation of Box C <input checked="" type="checkbox"/> See patent family annex		
* Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier application or patent but published on or after the international filing date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but later than the priority date claimed "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art "&" document member of the same patent family		
Date of the actual completion of the international search 20 August 2001		Date of mailing of the international search report 31 AUGUST 2001
Name and mailing address of the ISA/AU AUSTRALIAN PATENT OFFICE PO BOX 200, WODEN ACT 2606, AUSTRALIA E-mail address: pct@ipaustalia.gov.au Facsimile No. (02) 6285 3929		Authorized officer <i>Anthea Harvie</i> ANTHEA HARVIE Telephone No: (02) 6283 2552

INTERNATIONAL SEARCH REPORT
Information on patent family members

International application No.
PCT/AU01/00795

This Annex lists the known "A" publication level patent family members relating to the patent documents cited in the above-mentioned international search report. The Australian Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

Patent Document Cited in Search Report				Patent Family Member	
WO	9832768	AU	58715/98	EP	975663
END OF ANNEX					

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ BLACK BORDERS
- ☐ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☒ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☐ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.